Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VIVID-DME: Aflibercept in Diabetic Macular Edema
NCT01331681Phase 3Completed
- Sponsor
- Bayer
- Start
- May 2011
- Primary completion
- Jun 2013
- Modality
- Engineered Antibody Formats, Fc-Fusion Proteins
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of aflibercept in diabetic macular edema (DME) (3 arms), sponsored by Bayer. Primary endpoint: Best Corrected Visual Acuity at 52 weeks. Started May 2011; status: completed.
02
Drugs
aflibercept
03
Conditions
diabetic macular edema (DME)
Beyond the preview
Go deeper on NCT01331681.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01331681.